Pharming Group (NASDAQ:PHAR) Stock Price Up 5.7% – What’s Next?

Pharming Group (NASDAQ:PHAR)’s share price was up 5.7% on Thursday . The stock traded as high as $8.76 and last traded at $8.90. Approximately 1,935 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 4,843 shares. The stock had previously closed at $8.42.

Analyst Ratings Changes

Several brokerages have issued reports on PHAR. Oppenheimer cut their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th.

Pharming Group Trading Down 1.0 %

The stock’s 50-day simple moving average is $9.21 and its 200-day simple moving average is $8.43. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.